<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13336">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01985607</url>
  </required_header>
  <id_info>
    <org_study_id>UP08-ALLAR</org_study_id>
    <nct_id>NCT01985607</nct_id>
  </id_info>
  <brief_title>Efficacy of a New Thickened Extensively Hydrolyzed Formula</brief_title>
  <acronym>ALLAR</acronym>
  <official_title>Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Cow's Milk Hypersensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Pharmaceuticals</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Kuwait: Joint Committee for the Protection of Human Subjects in Research</authority>
    <authority>Slovenia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cow Milk Allergy (CMA) occurs in 2 to 5 % of all infants. Reflux, regurgitation and vomiting
      are well recognised symptoms of CMA. The recommended treatment of CMA is an extensive
      hydrolysate. The North American Society of Pediatric Gastroenterology Hepatology and
      Nutrition (NASPGHAN) &amp; the  European Society of Pediatric Gastroenterology Hepatology and
      Nutrition (ESPGHAN) reflux guidelines have no strict recommendations for the treatment of
      distressed infants with reflux, suspected of CMA. One of the preferred proposed options is
      to thicken an extensive hydrolysate .

      This study aims at evaluating the additional value of a thickened extensive hydrolysate in
      children suspected of CMA and presenting with frequent regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patient dropped out for intolerance</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vandenplas' regurgitations score</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cow's milk protein hypersensitivity score</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth (weight, height, head circumference)</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth (weight, height, head circumference)</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth (weight, height, head circumference)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of daily regurgitations</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Protein Allergy</condition>
  <condition>Cow's Milk Protein Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Thickened</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>new extensively hydrolysed formula</intervention_name>
    <arm_group_label>Thickened</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Extensively hydrolysed formula</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  term born infants

          -  Having a Vandenplas' score of regurgitation of at least 2

          -  With suspected diagnosis of CMA because of clinical history/symptoms (based on a
             Cow's Milk Protein hypersensitivity (CMPH) score of 10 or more) and/or positive
             Immunoglobulin E (IgE) testing, radioallergosorbent test (RAST) or skin prick test

        Exclusion Criteria:

          -  Exclusively breast fed infants

          -  Fed with an extensively hydrolysed formula or amino acid formula
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippocration Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, Kuwait university</name>
      <address>
        <city>Safat</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatricians</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Greece</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
